A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy.

Seung-Hwan Jeong Sang Eun Yeon Su Youn Kim Tae Gyun Kwon Seong Soo Jeon Young Deuk Choi Dong Deuk Kwon Byung Ha Chung Sung-Hoo Hong Byung Hoon Kim Kyungmin Lee Sang Joon Shin Woo Suk Choi Sung Woo Park Taek Won Kang Seok-Joong Yun Jin Seon Cho See Min Choi Na-Ri Lee Cheol Kwak

Published in: Investigative and clinical urology (2023)

In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions.

Keyphrases

adverse drug
free survival
prostate cancer
locally advanced
radical prostatectomy
squamous cell carcinoma
randomized controlled trial
small cell lung cancer
public health
systematic review
electronic health record
emergency department
chemotherapy induced
radiation therapy